Synageva BioPharma announced positive data on sebelipase alfa in a clinical study of patients with lysosomal acid lipase (LAL) deficiency at the American Association for the Study of Liver Diseases’ AASLD Liver Meeting.
Rates of serologic testing for hepatitis B virus (HBV) conducted by the U.S. Department of Veterans Affairs (VA) were found to be suboptimal as recommended by the AASLD practice guideline, according to a presentation at the AASLD Liver Meeting.
Gilead Sciences announced results from three Phase 2 open-label studies investigating the efficacy and safety of an all-oral pan-genotypic regimen containing Sovaldi (sofosbuvir) and GS-5816 for the treatment of chronic hepatitis C virus (HCV) infection.
Enanta Pharmaceuticals announced results from AbbVie’s Phase 2b PEARL-I study with ABT-450/ritonavir and ombitasvir, an all-oral, interferon-free investigational treatment combining two direct-acting antivirals with or without ribavirin in patients with genotype 4 (GT4) chronic hepatitis C virus (HCV) infection.
Gilead Sciences announced results from several Phase 2 and Phase 3 studies evaluating the use of Harvoni (ledipasvir/sofosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection.